Lamotrigine administration in panic disorder with agoraphobia.
Several anticonvulsants, although as yet not lamotrigine (LTG), have been found useful in the treatment of panic disorder with (PDA) or without agoraphobia. We administered LTG (200 mg/d) to 4 outpatients with PDA, as an augmentation therapy (3 patients with chronic and severe agoraphobia) or monotherapy (1 drug-naive patient with first-onset PDA) in a 14-week trial. The patient under LTG monotherapy improved significantly, whereas PDA symptoms in 2 of the other patients improved to some extent.
Masdrakis
Vasilios G
VG
Eginition Hospital, 1st Department of Psychiatry, Athens University Medical School, Athens, Greece. vmasdrakis@med.uoa.gr
Papadimitriou
George N
GN
Oulis
Panagiotis
P
D000328:Adult; D000379:Agoraphobia / Q000150:complications* / Q000188:drug therapy*; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine